Introduction
The polo-like kinase (Plk) family of structurally related serine-threonine kinases are found in organisms as diverse as yeast and humans and appear to be critical regulators of both normal cell cycle progression and the cellular response to DNA damage (Glover et al., 1998; Donaldson et al., 2001; Dai et al., 2002b; Barr et al., 2004) . Four Plks have been identified in mammals: Plk1 (Plk), Plk2 (Snk), Plk3 (Fnk), and Plk4 (Sak), the latter kinase a highly divergent protein that has only recently been recognized as a bonafide family member (Glover et al., 1998; Donaldson et al., 2001; Hudson et al., 2001; Dai et al., 2002b; Ma et al., 2003b; Barr et al., 2004) . The human Plk1, 2, 3, and 4 genes have distinct chromosomal locations (Table 1 ) and expression profiles (see below), consistent with observations indicating that the kinases encoded by these loci have unique biological functions (Hudson et al., 2001; Ma et al., 2003a; Barr et al., 2004) . Plks are subject to multiple regulatory controls, including those operating at the gene expression, protein modification, and subcellular localization levels. In this article, we summarize the currently available Plk family member gene expression data and discuss how this largely descriptive information can nevertheless contribute to our understanding of Plk regulation and function.
Plk1 gene expression

Cells in culture
Various groups have shown that Plk1 (Plk), the most extensively characterized mammalian Plk family member, is an important regulator of mitosis, meiosis, and cytokinesis (Barr et al., 2004) . Consistent with these findings, it has been demonstrated that Plk1 gene expression is regulated during cell cycle progression, with peak levels occurring at M phase. In serumstimulated NIH 3T3 cells, Plk1 mRNA expression is first detected at 14 h postserum addition and maximal levels are observed at 20-23 h (Lake and Jelinek, 1993; Lee et al., 1995) . Plk1 protein expression and enzymatic activity levels are regulated in a similar manner (Lee et al., 1995) (Figure 1 ). Serum-induced Plk1 mRNA expression has also been observed in human A-431 epidermoid carcinoma cells (Holtrich et al., 1994) , mouse and porcine fetal fibroblasts (Anger et al., 2003) , and rat cardiac fibroblasts (Georgescu et al., 1997) .
Plk1 expression and activity has also been monitored in many different cell types that have either been arrested at various points in the cell cycle using chemical agents (e.g. mimosine, aphidicolin, nocodozole, hydroxyurea), fractionated by centrifugal elutriation, or synchronized at the G1-S boundary by double thymidine block and then released. In general, these studies have demonstrated that Plk1 expression/activity is low in G0, G1, and S, begins to increase in G2, and peaks in M phase (Lake and Jelinek, 1993; Golsteyn et al., 1994; Golsteyn et al., 1995; Hamanaka et al., 1995; Lee et al., 1995; Uchiumi et al., 1997; Ferris et al., 1998; Roshak et al., 2000; Alvarez et al., 2001; Anger et al., 2003) .
Plk1 is targeted for degradation via the ubiquitinproteosome pathway as cells exit mitosis Lindon and Pines, 2004) . Indeed, Plk1 contains a destruction box-like motif and is a substrate of the anaphase-promoting complex/cyclosome, a cell cycleregulated ubiquitin ligase (Kotani et al., 1999; Lindon and Pines, 2004) . Intracellular Plk1 levels also appear to be controlled by the molecular chaperone Hsp90, since Plk1 expression levels decrease when cells are treated with compounds that disrupt Plk1:Hsp90 binding (Simizu and Osada, 2000; Blank et al., 2003) .
Plk1 gene regulation has also been observed in several other experimental systems; in general, these studies demonstrate a positive correlation between Plk1 levels and cell proliferation. For example, Plk1 expression increases when the mitogen phytohemagglutinin is added to human peripheral blood lymphocytes (Holtrich et al., 1994; Yuan et al., 1997) , but decreases during nerve growth factor-induced rat PC12 cell differentiation (Hamanaka et al., 1994) , during phorbol myristate acetate (PMA)-induced human U937 and HL-60 monocytic cell differentiation (Yuan et al., 1997) , and when human glioma cell growth is inhibited using antisense oligonucleotides targeting phospholipase C-gamma mRNA (Dietzmann et al., 2002) . Also, DNA-damaging agents that promote cell cycle arrest have been reported to decrease Plk1 gene expression levels in mammalian cells (Ree et al., 2003; Ando et al., 2004) . In breast cancer cells, ionizing radiation-induced Plk1 mRNA downregulation is dependent on CHEK1 signaling and BRCA1 function (Ree et al., 2003) .
Normal adult tissues and tumor specimens
Plk1 is expressed at the highest levels in tissues with actively proliferating cell populations; for example, the placenta (Golsteyn et al., 1994; Hamanaka et al., 1994; Holtrich et al., 1994; Takai et al., 1999; Yoshimatsu et al., 1999; Wolf et al., 2000) , spleen (Clay et al., 1993; Lake and Jelinek, 1993; Golsteyn et al., 1994) , ovary (Lake and Jelinek, 1993; Golsteyn et al., 1994; Hamanaka et al., 1994; Matsubara et al., 1995; Takai et al., 1999) , and testis (Lake and Jelinek, 1993; Golsteyn et al., 1994; Matsubara et al., 1995; Syed and Hecht, 1998) . Indeed, Northern blot hybridization experiments have shown that Plk1 transcripts are either undetectable or present at very low levels in most other adult tissues, including the liver, kidney, brain, thymus, intestine, lung, pancreas, heart, stomach, and skin (Clay et al., 1993; Lake and Jelinek, 1993; Golsteyn et al., 1994; Hamanaka et al., 1994; Holtrich et al., 1994; Georgescu et al., 1997; Wolf et al., 2000) . Interestingly, although Plk1 protein expression cannot be detected in normal brain tissue specimens, it can be detected in brain tissue from patients with Alzheimer's disease (Harris et al., 2000) .
Numerous studies have demonstrated that Plk1 gene expression is frequently upregulated in tumor tissues, consistent with the proposal that this Plk family member has a positive role in cell growth control. For example, an increase in Plk1 mRNA levels has been found in human breast (Holtrich et al., 1994; Wolf et al., 2000) , esophageal carcinoma (Holtrich et al., 1994; Tokumitsu et al., 1999) , head and neck squamous cell carcinoma (Knecht et al., 1999) , liver (Ando et al., 2004) , and lung Figure 1 Plk1, 2, 3, and 4 mRNA and protein expression patterns in serum-stimulated murine NIH 3T3 cells. References: Plk1 (Lake and Jelinek, 1993; Lee et al., 1995) ; Plk2 (Simmons et al., 1992; Ma et al., 2003b) ; Plk3 (Donohue et al., 1995; Chase et al., 1998) ; and Plk4 (Fode et al., 1996) (Holtrich et al., 1994; Wolf et al., 1997; Wikman et al., 2002; Ando et al., 2004) tumor biopsies compared to corresponding adjacent normal tissue specimens. Also, high levels of Plk1 protein expression have been detected in breast (Yuan et al., 1997; Wolf et al., 2000) , ovarian (Takai et al., 2001; Weichert et al., 2004) , head and neck squamous cell carcinoma (Knecht et al., 2000) , and melanoma tumor specimens using an immunohistochemical approach. In some of the studies described above, a statistically significant correlation was found between high Plk1 expression and low patient survival, suggesting that Plk1 may have utility as a negative prognostic indicator for some tumor types Knecht et al., 1999; Tokumitsu et al., 1999; Knecht et al., 2000; Strebhardt et al., 2000; Weichert et al., 2004) .
Plk2 gene expression
Cells in culture
Plk2 (Snk) may primarily function as a regulator of G1 progression in mammalian cells (Ma et al., 2003a) , and this finding is consistent with the Plk2 gene expression pattern observed in cycling cells. The Plk2 gene was initially identified in the early-1990s as a serum-and PMA-inducible immediate-early response gene in NIH 3T3 cells (Simmons et al., 1992) . Indeed, it has been shown that Plk2 mRNA levels transiently increase following serum stimulation of quiescent murine NIH 3T3 fibroblasts (Simmons et al., 1992) , mouse fetal fibroblasts (Anger et al., 2003) , porcine fetal fibroblasts (Anger et al., 2003) , and human lung fibroblasts (Liby et al., 2001) , with peak expression at 0.5-1 h postserum addition. Plk2 protein levels also transiently increase in serum-stimulated NIH 3T3 cells, with a temporal expression pattern similar to that of Plk2 mRNA (Ma et al., 2003b) (Figure 1) . Finally, the Plk2 protein expressed in early G1 has a fast turnover rate (half-life of B15 min) and is catalytically active (Ma et al., 2003b) . Serum contains numerous polypeptide growth factors (e.g. platelet-derived growth factor) and these factors generally act via binding to specific cell surface tyrosine kinase receptors, activation of the Ras-Raf-MEK-ERK signal transduction pathway, and induction of immediate-early, delayed-early, and late response genes (Winkles, 1998; Schlessinger, 2000) . Therefore, one might predict that expression of Plk2, an immediate-early response gene, would be elevated in H-Ras-transformed cells with permanent ERK activation, but this is not the case. In expression profiling experiments conducted by Zuber et al. (2000) , Plk2 gene expression was significantly downregulated in H-Ras-transformed rat embryo fibroblasts compared to nontumorigenic, control fibroblasts. This result suggests that serum stimulation of Plk2 gene transcription may not be mediated by ERK pathway activation; however, it is also possible that Plk2 gene expression is extinguished in the H-Ras-transformed cell line because of genetic alterations at the Plk2 locus.
Plk2, like Plk1 (discussed above) and Plk3 (see below), is not only a growth factor-responsive gene but also a cellular stress-responsive gene. Many types of cellular stress, including DNA damage and hypoxia, activate the transcription factor p53, and the subsequent induction or repression of p53 target genes generally results in cell cycle arrest and apoptotic cell death (Ryan et al., 2001) . Two studies have established a link between DNAdamaging agents, p53, and the regulation of Plk2 gene expression. In the first study, Shimizu-Yoshida et al. (2001) found that X-ray irradiation of human thyroid cells induced Plk2 mRNA expression, and although they reported that the putative p53-binding sites in the human Plk2 promoter were necessary for this response, they were unable to demonstrate a direct interaction between p53 and a DNA fragment containing these sites. In a more recent study, Burns et al. (2003) demonstrated that when human cell lines were treated with either DNA-damaging agents or exposed to UV light, Plk2 mRNA expression was induced, and this response was dependent on cellular expression of wildtype p53 protein. Furthermore, they reported that Plk2 mRNA induction occurred in tissues harvested from irradiated wild-type mice but not irradiated p53-null mice. They were also able to show p53 binding to the Plk2 promoter. Additional experiments performed by this group indicate that stress-induced Plk2 protein may function to prevent mitotic catastrophe following spindle damage.
Normal adult tissues and tumor specimens
Plk2 mRNA is expressed in a tissue-specific manner in vivo. Plk2 transcripts have been detected in mouse brain, heart, and lung but not thymus, spleen, liver, kidney, or intestine (Simmons et al., 1992) . In a much larger survey of human tissue RNA samples, Liby et al. (2001) found relatively high levels of Plk2 mRNA in the testis, mammary gland, and spleen and intermediate levels in the brain, heart, uterus, and trachea. When this group examined Plk2 mRNA expression in different anatomical regions of the brain, they found a range of expression levels, with highest expression in putamen and occipital lobe and no detectable expression in the cerebellum. Plk2 gene expression levels in human tumor specimens have not yet been reported. Both Plk2 and Plk3 gene expression levels in the rat brain increase in response to stimuli that produce synaptic plasticity (Kauselmann et al., 1999) . Specifically, when neuronal activity is stimulated using seizure-inducing chemicals or long-term potentiation is induced using high-frequency orthodromic stimulation, Plk2 and Plk3 mRNA and protein levels rapidly increase and the two kinases are targeted to the dendrites of postmitotic neurons. These data suggest that these two Plk family members may perform functions in the brain that are quite distinct from their cell cycle regulatory activities.
Plk3 gene expression
Cells in culture
The precise role of Plk3 (Fnk) in mammalian cells is not yet established, but it appears to be primarily involved in the cellular response to DNA damage (Barr et al., 2004) . Plk3 was initially identified in the mid-1990s as a fibroblast growth factor (FGF)-inducible immediateearly response gene in murine NIH 3T3 cells (Donohue et al., 1995) . Maximum levels of Plk3 mRNA expression are detected 1 h after FGF or serum stimulation of quiescent NIH 3T3 cells, and expression returns to basal levels by 8 h (Donohue et al., 1995) . However, Plk3 protein levels remain relatively constant in mitogenstimulated NIH 3T3 cells (Chase et al., 1998; Bahassi et al., 2002) (Figure 1 ). Serum and/or growth factor treatment also promotes Plk3 mRNA induction during early G1 in the human MO7e, Dami, and K562 cell lines (Li et al., 1996) , as well as in mouse and porcine fetal fibroblasts (Anger et al., 2003) . In mitogen-stimulated human fibroblasts, Plk3 mRNA levels peak at 2 h ( Figure 2a ) but Plk3 protein is expressed throughout the cell cycle (Figure 2b) . Therefore, data obtained using both murine and human fibroblasts demonstrate that, in contrast to what is found for Plk1 and Plk2, the expression of Plk3 mRNA and protein is not coordinately regulated in mammalian cells. We have found that the Plk3 protein present in human dermal fibroblasts is very stable (Figure 3a) , and this likely provides an explanation as to why Plk3 protein is present at all stages of the cell cycle even though Plk3 mRNA expression is restricted to G1. In addition, recent studies from our laboratory examining the subcellular location and turnover of murine Plk3 protein overexpressed in transfected cells demonstrated that activated Plk3 is rapidly degraded in the nucleus via the ubiquitin-proteosome pathway (Alberts and Winkles, 2004) . Since it appears that Plk3 normally exists in cycling cells as a catalytically inactive protein (Bahassi et al., 2002) , one would predict that in order to have a long half-life it would need to be sequestered in the cytoplasm. This is in fact what we have observed for the endogenous Plk3 present in human dermal fibroblasts (Figure 3b) .
Changes in Plk3 mRNA expression have also been noted in three other experimental systems. Holtrich et al. (2000) found that Plk3 transcript levels were higher in adherent primary human monocytes compared to nonadherent cells and these authors suggested that Plk3 could participate in adhesion-related signal transduction pathways. Waelput et al. (2000) reported that leptin treatment of a PC12 cell line stably expressing the mouse leptin receptor induced Plk3 mRNA expression. In addition, intraperitoneal administration of recombinant leptin into starved wild-type mice or leptin-deficient ob/ob mice induced Plk3 mRNA expression in the liver. Finally, in a recent report by Ando et al. (2004) , it was shown that cisplatin treatment of human neuroblastoma cells increases Plk3 mRNA expression levels. Therefore, Figure 2 Regulation of Plk3 mRNA and protein expression in mitogen-stimulated human fibroblasts. (a) Human dermal fibroblasts (Clonetics) were cultured in basal, serum-and growth factorfree medium for 48 h, and then this medium was replaced with normal growth medium containing fetal bovine serum, FGF-2, and insulin. Cells were harvested at the indicated time points, RNA was isolated, and equivalent amounts of RNA were subjected to Northern blot hybridization analysis using a human Plk3 cDNA probe. In the bottom panel, a photograph of the ethidium bromidestained 18S rRNA species is shown to demonstrate that equivalent amounts of RNA were present in each gel lane. (b) Fibroblasts were treated as above, cell lysates were prepared, and equivalent amounts of total cell protein were subjected to SDS-PAGE and Western blot analysis using anti-Plk3, anti-cyclin D1, and anticyclin B1 monoclonal antibodies (BD Biosciences). Cyclin expression was monitored to confirm mitogen-stimulated cell cycle progression Figure 3 Plk3 protein stability and subcellular location in human fibroblasts. (a) Human dermal fibroblasts were either left untreated (0 h time point) or treated with the protein synthesis inhibitor cycloheximide (CHX; 10 mg/ml), and then harvested at the indicated time points. Cell lysates were prepared and equivalent amounts of total cell protein were subjected to SDS-PAGE and Western blot analysis using an anti-Plk3 monoclonal antibody. (b) Human fibroblasts were harvested and cytoplasmic and nuclear fractions were isolated as described (Alberts and Winkles, 2004) . The protein concentration of each cytoplasmic fraction was determined and the same volumes of the cytoplasmic and nuclear fractions were used for SDS-PAGE and Western blot analysis using anti-Plk3, anti-Src (Upstate), and anti-histone H1 (Santa Cruz) monoclonal antibodies. Src and histone H1 expression was monitored to confirm efficient subcellular fractionation Plk3, like Plk1 and Plk2, is a cellular stress-regulated gene.
Normal adult tissues and tumor specimens
Plk3 mRNA is expressed at relatively low levels in most adult tissue types; in a survey of 12 mouse tissues, high levels were detected only in the skin, lung, and brain (Donohue et al., 1995) . As mentioned above, Plk3 gene expression in the rodent brain is induced by stimuli that produce synaptic plasticity (Kauselmann et al., 1999) . In a survey of 16 human tissues, relatively high levels of Plk3 mRNA expression were detected in the placenta, ovary, and lung (Li et al., 1996) .
Several studies have examined Plk3 expression in human tumor specimens. Three groups reported that Plk3 mRNA expression was frequently reduced in lung tumor specimens in comparison to adjacent uninvolved tissue harvested from the same patients (Li et al., 1996; Holtrich et al., 2000; Ando et al., 2004) . Also, Plk3 mRNA downregulation has been detected in uterus (Ando et al., 2004) , bladder (Ando et al., 2004) , and head and neck squamous cell carcinoma (Dai et al., 2000) specimens. However, an increase in Plk3 mRNA levels has been found in some hepatoblastomas (Ando et al., 2004) and when Plk3 protein levels were compared in a panel of normal ovary and ovarian carcinoma samples using an immunohistochemical approach, moderately higher expression levels were noted in the tumor specimens (Weichert et al., 2004) .
Plk3 mRNA expression levels have also been compared in chemically induced rat colon tumors versus normal colonic mucosa using an RT-PCR approach (Dai et al., 2002a) . Plk3 mRNA expression was downregulated in all of the colon tumors and this effect was most pronounced in rats fed a high fat, corn oil diet.
In summary, Plk3 gene expression appears to decrease during the development of some, but not all, types of tumors. Since Plk3 may primarily function in the DNA damage response pathway, reduced Plk3 levels could contribute to the genomic instability characteristic of tumor cells.
Plk4 gene expression
Cells in culture
Plk4 (Sak) may primarily play a role in M phase progression (Hudson et al., 2001 ) and this possibility is supported by data demonstrating Plk4 mRNA expression at this cell cycle stage (Fode et al., 1996) . In this study, Plk4 mRNA levels were monitored in murine NIH 3T3 fibroblasts under three culture conditions: (1) as cells exited the cell cycle due to contact inhibition, (2) after quiescent, growth-arrested cells were stimulated to enter the cell cycle by serum addition, and (3) after cells were released from a nocodazole-induced mitotic block. The results demonstrated that Plk4 mRNA expression is relatively low in both quiescent, G0 phase cells and in early-to-mid-G1 phase cells and then increases beginning in the late G1 phase of the cell cycle. Plk4 mRNA expression is relatively high in the S, G2, and M phases (Figure 1) . It is not known at the present time whether Plk4 protein levels or kinase activity are regulated during the cell cycle in a similar manner.
Plk4 gene expression in mammalian cells is also controlled at the post-transcriptional, protein degradation level. There are two murine Plk4 isoforms, Plk4-a and Plk4-b, which differ in the size of their C-terminal, noncatalytic domain (Fode et al., 1994) . It has been reported that when Plk4-a is overexpressed in CHO cells, it is ubiquitinated and has a relatively short halflife (2-3 h) (Fode et al., 1996) . Indeed, the murine Plk4-a protein contains three clusters of PEST sequences, one located in the N-terminal catalytic domain and two located close to each other in the C-terminal region. PEST sequences frequently target proteins for rapid degradation, in some cases via the ubiquitin-proteosome pathway (Rechsteiner and Rogers, 1996) . These PEST sequences are also found in human Plk4, and it has been shown by Yamashita et al. (2001) that deletion of these sequences can increase Plk4 levels in transfected cells. In addition, these authors reported that PESTmediated proteolysis of human Plk4 may be regulated by Tec, a cytoplasmic tyrosine kinase. It appears that Tec phosphorylation promotes Plk4 stabilization, and if so, this would provide a link between intracellular tyrosine kinase signaling pathways, Plk4 levels, and possibly Plk4 kinase activity.
Normal adult tissues and tumor specimens
Plk4 mRNA expression has been detected in only a few adult tissues by Northern blot hybridization analysis. In the mouse, Plk4 mRNA was found at the highest level in the testis, at an intermediate level in the spleen and thymus, and not at all in the brain, heart, kidney, liver, or ovary (Fode et al., 1994) . Similarly, Karn et al. (1997) surveyed 16 different human tissues and the highest level of Plk4 mRNA expression was again detected in the testis, a tissue containing actively dividing somatic and germ cells. Plk4 gene expression levels in human tumor specimens have not yet been reported.
Summary
The Plk family genes are differentially expressed during normal cell cycle progression and after DNA-damaging agents are added to cycling cells. Also, intracellular Plk1, 2, 3, and 4 levels are controlled by both transcriptional and post-transcriptional (i.e. protein degradation) mechanisms. The Plk family genes are expressed in a tissue-specific manner in vivo, and in the case of Plk1, there exists a good correlation between expression levels and the presence of actively dividing cells. It has also been reported that, in general, Plk1 expression increases and Plk3 expression decreases during tumor development. In conclusion, the studies reviewed here demonstrate that Plk family members are subject to regulation at the gene expression level. In addition, they are consistent with the proposal that while the Plk1, 2, and 4 proteins are expressed and activated at specific stages of the cell cycle and mainly function as positive regulators of cell cycle progression, Plk3 is a constitutively expressed, DNA damageactivated protein involved in cell cycle arrest.
